ADVANCED ACCELERATOR APPLICATIONS
Advanced Accelerator Applications (AAA), is a European Pharmaceutical Group founded in 2002 by Italian academics as a spin-off of the “European Organization for Nuclear Research” (CERN), Geneva, Switzerland), to develop innovative diagnostic and therapeutic products. AAA’s main focus is in the field of Molecular Imaging and targeted, individualized therapy for the management of patients with serious conditions (Personalized Medicine). AAA is a European leader in the production and co... mmercialization of PET (Positron Emission Tomography) radiopharmaceuticals. PET is a state-of-the-art diagnostic technique that is today mainly used in clinical oncology, cardiology and neurology. AAA also produces a broad range of SPECT products. AAA currently has 17 production and R&D facilities able to manufacture both diagnostics and therapeutic MNM products, and has over 300 employees in 11 countries (France, Italy, UK, Germany, Switzerland, Spain, Poland, Portugal, Israel, United States and Canada).
ADVANCED ACCELERATOR APPLICATIONS
Industry:
Health Diagnostics Pharmaceutical Therapeutics
Founded:
2002-01-01
Address:
Saint-genis-pouilly, Rhone-Alpes, France
Country:
France
Website Url:
http://www.adacap.com
Total Employee:
251+
Status:
Active
Contact:
33 4 50 99 30 70
Email Addresses:
[email protected]
Total Funding:
144.29 M USD
Technology used in webpage:
Domain Not Resolving Mobile Non Scaleable Content IPv6 Amazon Virginia Region Microsoft Microsoft Azure New Relic Shutterstock Apple Whitelist YouTube IFrame Upload
Similar Organizations
Apellis Pharmaceuticals
Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
Altamira Therapeutics
Altamira Therapeutics develops novel pharmaceutical therapies to prevent and treat severe inner ear disorders.
Axcella
Axcella is a biotechnology company that treats diseases using endogenous metabolic modulators.
Imvax
Imvax is a biotechnology company focused on the development of novel patient-specific vaccines and immunotherapy strategies.
Vetsource
Vetsource provides comprehensive solutions to those who care for pets - veterinarians and pet owners.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Rock Springs Capital
Rock Springs Capital investment in Venture Round - Advanced Accelerator Applications
T. Rowe Price
T. Rowe Price investment in Venture Round - Advanced Accelerator Applications
Adage Capital Management
Adage Capital Management investment in Venture Round - Advanced Accelerator Applications
HBM Healthcare Investments AG
HBM Healthcare Investments AG investment in Venture Round - Advanced Accelerator Applications
Tamburi Investment Partners
Tamburi Investment Partners investment in Venture Round - Advanced Accelerator Applications
Seventure Partners
Seventure Partners investment in Private Equity Round - Advanced Accelerator Applications
Naxicap Partners
Naxicap Partners investment in Private Equity Round - Advanced Accelerator Applications
Official Site Inspections
http://www.adacap.com Semrush global rank: 4.63 M Semrush visits lastest month: 2.15 K
- Host name: 104.18.37.101
- IP address: 104.18.37.101
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Advanced Accelerator Applications"
Advanced Accelerator Applications - Crunchbase
Organization. Advanced Accelerator Applications . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. About. AAA is an …See details»
Advanced Accelerator Applications | LinkedIn
Advanced Accelerator Applications | 37,655 followers on LinkedIn. We are your partner of choice in Europe for precision diagnostic solutions for positron emission tomography (PET) imaging – …See details»
S. BUONO | CEO | Advanced Accelerator Applications …
Advanced Accelerator Applications SA · www.adacap.com. Contact. ... Stefano Buono is an accomplished physicist and alumnus of The European …See details»
Advanced Accelerator Applications Information
Adacap.com; novartis.com; 2 845271XXXX; 845729XXXX; Thierry Barsalou Deputy Head IT and Senior Global Head Service Delivery at Advanced Accelerator Applications Geneva, GE, CH …See details»
Advanced Accelerator Applications - ZoomInfo
Jan 11, 2024 Advanced Accelerator Applications contact info: Phone number: +33 450993070 Website: www.adacap.com What does Advanced Accelerator Applications do? Founded in …See details»
Advanced Accelerator Applications — Wikipédia
Advanced Accelerator Applications (AAA) (NASDAQ: AAAP) est un groupe pharmaceutique spécialisé en médecine nucléaire moléculaire. L’activité du groupe est axée sur les 3 …See details»
Adacap: un laboratoire à la pointe de la médecine …
Nov 21, 2023 Adacap (ou Advanced Accelerator Applications) est un laboratoire radiopharmaceutique français fondé en 2002 dans le but de commercialiser une technologie de radiomédicaments diagnostiques. Initialement, ces molécules …See details»
Orphanet: Advanced Accelerator Applications
Contact email: [email protected]. Institution's website EUGT Number: 260300 Contacts. Professionals: ADVANCED ACCELERATOR APPLICATIONS , INFORMATION …See details»
ADVANCED ACCELERATOR APPLICATIONS - Eurasanté
Adacap.com. Contact [email protected]. Découvrez les entreprises du parc : HealthSquad (ex Lighthouse-Useradventure) Interstellab (PHENOTYP) SIB – AGENCE DE LILLE. B …See details»
Siemens Healthineers Acquires Advanced Accelerator Applications ...
Dec 11, 2024 Siemens Healthineers has concluded the acquisition from Novartis of Advanced Accelerator Applications Molecular Imaging, a European manufacturing and distribution …See details»
Novartis announces the planned acquisition of Advanced …
Basel, October 30, 2017 - Novartis announced today, that it has entered a memorandum of understanding with Advanced Accelerator Applications (AAA) under which Novartis intends to …See details»
Cartography of the Geneva Health Hub - Health field concerned ...
Advanced Accelerator Applications is reimagining nuclear medicine and cancer care. Its mission is to transform patients’ lives by developing and delivering targeted radioligand therapies and …See details»
Welcome to the PLUVICTO(TM) Resource HUB
Advanced Accelerator Applications Canada, Inc., a Novartis Company. 2810 Matheson Blvd. E., Suite 700 Mississauga, Ontario, L4W 4X7 Canada www.adacap.comSee details»
Health Canada approves PLUVICTO™ as first targeted ... - Newswire
Sep 7, 2022 Health Canada approves PLUVICTO™ as first targeted radioligand therapy for progressive PSMA‑positive metastatic castration-resistant prostate cancer FrançaisSee details»
Radiopharmaceutical cancer treatment Lutathera® now available …
Oct 8, 2020 Lutathera is the first and only therapeutic radiopharmaceutical approved by Health Canada for the treatment of GEP-NETs; Lutathera directly targets tumours by binding to …See details»
Advanced Accelerator Applications Announces $3.9 Billion
Oct 30, 2017 [email protected] Tel: + 1-212-235-2395. AAA Investor Relations Jordan Silverstein Head of Investor Relations [email protected]See details»
Advanced Accelerator Applications Receives Positive CHMP
Jun 6, 2019 Advanced Accelerator Applications Receives Positive CHMP Opinion for LysaKare ® for Reduction of Kidney Exposure to Radiation During Peptide Receptor Radionuclide …See details»
Advanced Accelerator Applications SA (Advanced Accelerator …
了解Advanced Accelerator Applications SA (Advanced Accelerator Applications SA)公司的药物管线，治疗领域，技术平台，以及它的45项临床试验, 10篇新闻和8篇文献，疾病领域:肿瘤，神 …See details»
Advanced Accelerator Applications to Build Targeted Radioligand …
Jun 30, 2020 SAINT-GENIS-POUILLY, France, June 30, 2020 /PRNewswire/ -- Advanced Accelerator Applications S.A. (AAA), a Novartis company, today announced it has executed a …See details»
A Randomized clinical trial evaluating the impact on survival and ...
4 days ago The 2015 World Health Organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification. J Thorac Oncol Off Publ Int …See details»